By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Dragonfly Therapeutics 

Cambridge  Massachusetts    U.S.A.
Phone: 617-780-1660 Fax: n/a


Dragonfly Therapeutics is a discovery-stage company developing drugs to stimulate immune responses against cancer. We are developing novel first-in-class therapeutics targeted at natural killer cells and other cells of the innate immune system. Our scientific founders are major figures in cancer biology and immunology and have launched Dragonfly to harness the power of the immune system to provide breakthrough cancer treatments for patients.


July 2015


Co-Founder and CEO: William Haney

Co-Founder: Dr. Tyler Jacks

Co-Founder: Dr. David Raulet

Key Statistics

Ownership: Private

Web Site: Dragonfly

Company News
Dragonfly Appoints World Leader In NK Therapeutics As Chief Scientific Officer 6/26/2017 9:28:23 AM
Disney-Backed Dragonfly Nabs $33 Million From Biotech Bestie Celgene (CELG) 6/12/2017 7:09:43 AM
Dragonfly Adds Natural Killer Cell-Based Cancer Immunotherapy Expert To Its Scientific Advisory Board 5/23/2017 7:57:47 AM
Dragonfly Announces Head Of Biology 5/16/2017 10:18:44 AM
Dragonfly Completes New Investment Round 5/15/2017 9:00:06 AM
Leading Protein Scientist Dr. Asya Grinberg Joins Dragonfly As Head Of Biologics 5/1/2017 10:27:15 AM
Dragonfly Release: Company Adds Technology Investor And Leading Advertising Company CEO To Its Board Of Directors 1/11/2017 10:03:55 AM
Dragonfly Adds Expert In Protein Engineering And Structure To Its Scientific Advisory Board 11/15/2016 7:36:23 AM
Dragonfly Adds Leading Lymphoma Specialist To Its Scientific Advisory Board 9/19/2016 8:12:32 AM